CD8A and cancer: While STING agonists stimulate the antitumor immune factors, such as cytotoxic CD8+ T cells, they also up-regulate the expression of programmed death ligand 1 (PD-L1) in cancer cells (27–31), which inevitably attenuates the effect of the activated CD8+ T cells and causes immune escape of cancer cells.